Literature DB >> 35766509

Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Alice J Hsu1, Pranita D Tamma2, Brian T Fisher3.   

Abstract

Invasive aspergillosis (IA) is associated with significant morbidity and mortality. Voriconazole remains the drug of choice for the treatment of IA in children; however, the complex kinetics of voriconazole in children make dosing challenging and therapeutic drug monitoring (TDM) essential for treatment success. The overarching goal of this review is to discuss the role of voriconazole, posaconazole, isavuconazole, liposomal amphotericin B, echinocandins, and combination antifungal therapy for the treatment of IA in children. We also provide a detailed discussion of antifungal TDM in children.

Entities:  

Keywords:  invasive aspergillosis; isavuconazole; posaconazole; therapeutic drug monitoring, immunocompromised children; voriconazole

Mesh：

Substances：

Year:  2022        PMID： 35766509      PMCID： PMC9295552          DOI： 10.1128/aac.02156-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  189 in total

1.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.

Authors:  N Decembrino; K Perruccio; M Zecca; A Colombini; E Calore; P Muggeo; E Soncini; A Comelli; M Molinaro; B M Goffredo; S De Gregori; I Giardini; L Scudeller; S Cesaro
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors.

Authors:  I Gueta; R Loebstein; N Markovits; Y Kamari; H Halkin; G Livni; H Yarden-Bilavsky
Journal:  Eur J Clin Pharmacol       Date:  2017-06-17       Impact factor: 2.953

Review 4.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

7.  Influence of inflammation on voriconazole metabolism.

Authors:  M A Encalada Ventura; L F R Span; E R van den Heuvel; G M M Groothuis; J-W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

Review 8.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

9.  Inflammation is a potential risk factor of voriconazole overdose in hematological patients.

Authors:  Elodie Gautier-Veyret; Aurélie Truffot; Sébastien Bailly; Xavier Fonrose; Anne Thiebaut-Bertrand; Julia Tonini; Jean-Yves Cahn; Françoise Stanke-Labesque
Journal:  Fundam Clin Pharmacol       Date:  2018-12-07       Impact factor: 2.748

Review 10.  Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.

Authors:  Brian T Fisher; Paula D Robinson; Thomas Lehrnbecher; William J Steinbach; Theoklis E Zaoutis; Bob Phillips; Lillian Sung
Journal:  J Pediatric Infect Dis Soc       Date:  2018-08-17       Impact factor: 3.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.